Cargando…

Systemic and intratumoral 9-valent human papillomavirus vaccine treatment for squamous cell carcinoma in situ in a renal transplant recipient

Detalles Bibliográficos
Autores principales:	Nichols, Anna J., De Bedout, Valeria, Fayne, Rachel A., Burke, George W., Kirsner, Robert S., Ioannides, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109374/ https://www.ncbi.nlm.nih.gov/pubmed/32258300 http://dx.doi.org/10.1016/j.jdcr.2020.02.002

Ejemplares similares

Systemic 9-valent human papillomavirus vaccine for recalcitrant common cutaneous warts in preparation for renal transplant
por: Wyant, W. Austin, et al.
Publicado: (2022)

A Broad Safety Assessment of the 9-Valent Human Papillomavirus Vaccine
por: Yih, W Katherine, et al.
Publicado: (2021)

Systemic lupus erythematosus following human papillomavirus 9-valent vaccination
por: Wan, Yuehua, et al.
Publicado: (2022)

Extended surveillance to assess safety of 9-valent human papillomavirus vaccine
por: Sundaram, Maria E., et al.
Publicado: (2022)

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials
por: Costa, Ana Paula Ferreira, et al.
Publicado: (2017)

Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study
por: Rahman, Shams, et al.
Publicado: (2016)

Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence
por: SIGNORELLI, C., et al.
Publicado: (2017)

Off-Label 9-Valent Human Papillomavirus Vaccination for Actinic Keratosis: A Case Series
por: Wenande, Emily, et al.
Publicado: (2021)

The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2021)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

The sero-epidemiology of human papillomavirus among Caucasian transplant recipients in the UK
por: Casabonne, Delphine, et al.
Publicado: (2009)

Costs and Cost-Effectiveness of 9-Valent Human Papillomavirus (HPV) Vaccination in Two East African Countries
por: Kiatpongsan, Sorapop, et al.
Publicado: (2014)

Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes
por: Kharbanda, Elyse O., et al.
Publicado: (2021)

Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types
por: Nolan, Katrina M., et al.
Publicado: (2023)

Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
por: Ding, Yuan, et al.
Publicado: (2023)

Intratumoral therapies and in-situ vaccination for melanoma
por: Huppert, Laura A., et al.
Publicado: (2022)

Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2020)

Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium
por: Simoens, Steven, et al.
Publicado: (2021)

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices
por: Petrosky, Emiko, et al.
Publicado: (2015)

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women()
por: Ruiz-Sternberg, Ángela María, et al.
Publicado: (2017)

Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries
por: Garland, S M, et al.
Publicado: (2018)

Correction: Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2023)

Spotlight on the 9-valent HPV vaccine
por: Lopalco, Pier Luigi
Publicado: (2016)

Is there evidence for efficacy of human papillomavirus vaccination in solid organ transplant recipients?
por: Vinkenes, Emeline, et al.
Publicado: (2019)

Disseminated cutaneous immunoglobulin M macroglobulinosis associated with cryoglobulinemia and minimal residual disease of Waldenström macroglobulinemia
por: Fayne, Rachel, et al.
Publicado: (2019)

5. Observational Study of Routine Use of 9-Valent Human Papillomavirus Vaccine: Safe in More Than 140,000 Individuals
por: Hansen, John, et al.
Publicado: (2020)

Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021
por: Chen, Fuxing, et al.
Publicado: (2022)

Advances in Injectable In Situ-Forming Hydrogels for Intratumoral Treatment
por: Shin, Gi Ru, et al.
Publicado: (2021)

Everolimus and papillomavirus lesions in female renal transplant recipient: A case report
por: Simundic, T., et al.
Publicado: (2018)

Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis
por: Jiang, Y, et al.
Publicado: (2019)

Detection of Human Papillomavirus in Squamous Lesions of the Conjunctiva Using RNA and DNA In-Situ Hybridization
por: Peterson, Cornelia, et al.
Publicado: (2022)

Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients
por: Chockalingam, Ramya, et al.
Publicado: (2015)

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
por: Serrano, Beatriz, et al.
Publicado: (2012)

Risk of human papillomavirus infection and cervical intraepithelial lesions in Chinese renal transplant recipients
por: Chen, Ming, et al.
Publicado: (2022)

The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia
por: Mahumud, Rashidul Alam, et al.
Publicado: (2019)

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
por: Cordonnier, Catherine, et al.
Publicado: (2015)

Cutaneous HPV and alpha-mucosal 9-valent HPV sero-status associations
por: Rahman, Shams, et al.
Publicado: (2017)

In situ hybridization study on human papillomavirus DNA expression in benign and malignant squamous lesions of the esophagus.
por: Woo, Y. J., et al.
Publicado: (1996)

Aggressive Curettage-Cryosurgery for Human Papillomavirus-16 Associated Subungual Squamous Cell Carcinoma In Situ
por: Nordin, Peter, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c37nvktqt2gduaoppq6orrg7ed